Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21022459 | 1.00 | ALDH1A1 (0.44) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL19954135 | 0.96 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL23348425 | 0.94 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21022652 | 0.93 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21022458 | 0.93 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21131573 | 0.92 | PTGER4 (0.37) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL17930777 | 0.92 | KDM4E (0.45) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21132030 | 0.92 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL17930778 | 0.91 | KDM4E (0.46) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL20923101 | 0.90 | GSK3B (0.41) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11380849-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-20190198778-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11380849-B2 | Organic molecules for use in optoelectronic devices | OR10J3, NOX3, ORC3 | ALDH1A1 2468/4885LMNA 3331/4885HPGD 2992/4885 |
| US-20190198778-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | ORC3, OR10J3, NOX3 | ALDH1A1 2353/4885LMNA 3142/4885HPGD 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.